title: Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.
abstract: The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling pathway plays a fundamental role in many physiologic processes, including embryogenesis, adult tissue homeostasis, and wound healing, by orchestrating angiogenesis. Ligand-independent and ligand-dependent activation have been implicated in a broad range of human malignancies and promote cancer progression in tumors driven by FGF/FGFR oncogenic mutations or amplifications, tumor neoangiogenesis, and targeted treatment resistance, thereby supporting a strong rationale for anti-FGF/FGFR agent development. Efforts are being pursued to develop selective approaches for use against this pathway by optimizing the management of emerging, class-specific toxicity profiles and correctly designing clinical trials to address these different issues.
authors: Breast Cancer Unit, INSERM Unit U981, Gustave Roussy Institute, Villejuif, France.
authors: Maria Vittoria
authors: MV
authors: Dieci
authors: Monica
authors: M
authors: Arnedos
authors: Fabrice
authors: F
authors: Andre
authors: Jean Charles
authors: JC
authors: Soria
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000201:enzymology; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000201:enzymology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D017468:Receptors, Fibroblast Growth Factor / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction
chemical_list: D047428:Protein Kinase Inhibitors; D017468:Receptors, Fibroblast Growth Factor